Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

ARTICLES

Speed, scale, and simplicity in microarray analyzer

April 2026—CAP TODAY publisher Bob McGonnagle spoke on Feb. 19 with Thermo Fisher Scientific’s Ravi Gupta, MBA, VP and general manager; Robert Balog, PhD, MBA, senior director, research and development; and Poulomi Acharya, PhD, senior director, global product management and market development, genetic sciences.

Ravi Gupta
Gupta
Robert Balog
Dr. Balog

Read the article:

Bob McGonnagle: Thermo Fisher launched last fall the SwiftArrayStudio, a next-generation microarray analyzer that will support genomics research and clinical applications through the use of laboratory-validated and -developed tests. Ravi Gupta, what motivated the development of this analyzer?

Ravi Gupta: The SwiftArrayStudio resulted from listening to customers. It addresses the scientific and operational pressures observed in modern genomics. I call them the real-world needs. For decades, labs across human predictive genomics and agrigenomics have dealt with persistent challenges in workflow complexity, inconsistent turnaround times, and escalating costs. Continue reading …

Watch the full conversation:

This roundtable discussion is sponsored by Thermo Fisher Scientific.

No age too early: lab exposure through children’s books

April 2026—Two new children’s books aim to introduce young readers to the world of laboratory medicine. Mia the Marvelous Lab Explorer follows a young superhero pathologist as she helps diagnose a young boy with leukemia, while ABCs of Laboratory Medicine uses the alphabet to explain various laboratory concepts.

Alzheimer’s blood tests poised to lead

March 2026—For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—Alz-heimer’s disease has been linked to remarkably bright news as of late. Blood-based biomarkers, including two that garnered FDA approval last year, have cracked open the door to earlier diagnoses and therapeutic interventions, as well as the potential to reach more patients.

In MS diagnosis, the case for κ-FLC index

March 2026—An international panel of experts in multiple sclerosis and cerebrospinal fluid diagnostics reached a consensus in 2023, and they recommended including the determination of intrathecal kappa free light chain synthesis in the next revision of MS diagnostic criteria as an additional tool to measure intrathecal immunoglobulin synthesis.

Easing, clarifying of personnel requirements: ’25 accreditation checklists

March 2026—More flexibility and less burden sum up the personnel requirement changes in the accreditation program checklists released in December last year. The revisions to the CAP checklists stem from changes that the Centers for Medicare and Medicaid Services announced on June 23, 2025 in response to feedback the CMS had received about what it required in the CLIA final rule implemented on Dec. 28, 2024. The announcements were in CMS memorandum QSO-25-21-CLIA (CLIA Enforcement Discretion and Clarification on Personnel Regulations) and QSO-25-10-CLIA Revised (Revisions to State Operations Manual, Appendix C–Advance Copy).

Point-of-care HCV RNA testing: at what cost?

March 2026—A University of Washington study analyzed HCV testing costs across its system from 2017 to 2024, focusing on the public county hospital ED where one-third of diagnoses occur.

MARKETPLACE

TRENDING